PR Newswire
25 May 2023, 06:40 GMT+10
Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy.
MELBOURNE, Australia, May 25, 2023 /PRNewswire/ -- With the launch of a new website dedicated to their global clinical trials (https://hope4OA.com), Paradigm Biopharmaceuticals Ltd. (Paradigm Biopharma) aims to provide relief to millions of osteoarthritis (OA) sufferers worldwide by developing a new injectable drug.
Almost one in seven American adults has osteoarthritis
OA is a progressive degenerative disease affecting millions worldwide, with estimates reaching nearly half a billion sufferers. Due to their weight bearing role, 70% of all cases affect the hip or the knee.
Ex-Australian Football League (AFL) player Greg 'Diesel' Williams understands all too well how knee OA can have a devastating impact on your life. Greg explains "If you've got OA people really don't understand what we're going through. It's so painful. It's so sore. It's so, so hard to put up with. And it's about time we did something about it."
Dr Philip Bloom is a specialist sports physician with over 20 years' experience and specialist training in treating and managing musculoskeletal injuries and diseases to maximise function. Dr Bloom explains "We see many ex-athletes who have developed osteoarthritis of the knee. They've gone from being super performers to barely being able to go for a decent walk with their family, and it has quite a disabling effect on their whole life."
Paradigm shift for OA treatments
People with OA need alternative therapeutic solutions, as current therapies often don't provide sufficient relief, leaving people in pain and reducing their quality of life.
Dr Philip Bloom comments "Osteoarthritis of the knee is not just an isolated pain in the knee. It has a trickle-down effect on the rest of your life, particularly in regards to losing the ability to be active, which causes obesity, more aches and pains in other joints, and also psychological problems such as depression and anxiety."
Despite the huge need for effective treatments, there are still no registered treatments that can successfully stop or even slow the disease.
Paradigm Biopharma aims to provide hope to OA sufferers by developing a drug to help relieve pain and improve symptoms in people with knee OA.
This drug has been used to treat joint issues in the veterinary space for over 80 years and is registered for use by veterinarians in over 20 countries to treat arthritis in cats, dogs, horses, and even racing camels.
To facilitate current and potential trial participants, Paradigm has launched a new trial website called Hope4OA.com.
Here everyone can discover trial details and find answers to commonly asked questions. If interested, they are invited to complete an online questionnaire to determine their eligibility as a potential trial participant.
The new site hosts helpful explanations and instructional videos on clinical trials as well as providing links to patient support and further information.
To find out more, go to www.hope4oa.com
About Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).
Get a daily dose of Asia Bulletin news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Bulletin.
More InformationMOSCOW, Russia: Just hours after his sudden dismissal by President Vladimir Putin, Russia's former transport minister, Roman Starovoit,...
DHARAMSHALA, India: The Dalai Lama turned 90 on July 6, celebrated by thousands of followers in the Himalayan town of Dharamshala,...
ZAGREB, Croatia: A massive concert by popular Croatian singer Marko Perković, known by his stage name Thompson, has drawn widespread...
WASHINGTON, D.C.: Elon Musk's entry into the political arena is drawing pushback from top U.S. officials and investors, as his decision...
CULVER CITY, California: TikTok is preparing to roll out a separate version of its app for U.S. users, as efforts to secure a sale...
WASHINGTON, D.C.: President Donald Trump claimed he was unaware that the term shylock is regarded as antisemitic when he used it in...
LONDON, U.K.: This week, BP appointed Simon Henry, former Shell finance chief, to its board as a non-executive director effective September...
OTTAWA, Canada: With Canada Post struggling to maintain operations amid labour unrest, rivals like FedEx and UPS are stepping in to...
NEW YORK, New York - U.S. and global markets showed a mixed performance in Tuesday's trading session, with some indices edging higher...
PARIS, France: French military and intelligence officials have accused China of orchestrating a covert campaign to damage the reputation...
NEW DELHI, India: Birkenstock is stepping up its efforts to protect its iconic sandals in India, as local legal representatives conducted...
HONG KONG: China has fired back at the European Union in an escalating trade dispute by imposing new restrictions on medical device...